Guiding consumers since 2009

Pseudo-generics stealing the market

By Isabelle Coetzee

Large pharmaceutical companies, who produce pseudo-generic products following their patent expiring, are preventing true generic products from entering the market.  

“They create what are known as clones of their own products,” said Lynne du Toit, managing shareholder at Eurolab, a South African producer of generic oncology medication.

“These are sometimes manufactured on the same production line as the original product and then branded and labelled differently, or produced according to the same formula by an outsourced manufacturer,” she added.

Du Toit explained that these companies price their pseudo-generics below the price of their original products in order to compete with the real generic products.

The problem with this is that companies who create true generics have to pay for comparative studies and other supporting research before the medications can be approved.

“However, clone producers already hold much of that documentation because they hold the original patent, putting generic producers at a disadvantage,” said Du Toit.

“Clone products can actually be marketed before the patents expire and therefore get to the market more quickly, and are established as an alternative to the originals in the minds of medical professionals often long before generics appear on the market,” she added.

Du Toit illustrates how a true generic is actually a lot more affordable than a pseudo-generic: 




Original oncology medication

R1 789

Pseudo-generic of oncology medication


True generic of oncology medication



However, according to Du Toit, clones tend to make it to the market before generics do, and many doctors prefer to prescribe clones rather than generics, because they already have a relationship with the original pharmaceutical brand.

“This established relationship also makes it challenging for generic producers to build relationships with medical professionals, and we typically have to invest significantly more in marketing and brand building than the clone products do,” said Du Toit.

“The loser in all of this is the patient, who is compelled to pay unnecessary or excessive amounts for medication that could improve their quality of life, or indeed save their life,” she added.

Erik Roos, CEO of Pharma Dynamics, explained that the National Department of Health (NDoH) has a rule against one company selling the same medicine at a different price, but that pharmaceutical companies have found a loophole in the system.

“In many cases the brand name company will register a subsidiary with a different trade name to bypass this rule,” said Roos.

He pointed out that there have been several international reports confirming the uncompetitive nature of such practices, which have proven to lead to higher long-term medicine prices.

“The debate over affordable medication is hugely emotive in our country where 12 million people live under the breadline and where the poor often have to forego potential life-saving treatment because of the high price tag on medication,” said Roos.

Lianne Lutz, who’s a qualified pharmacist and wealth coach at Women’s Wealth, noted that pseudo-generics are often also referred to as authorised generics.

When considering the impact these clones may have on the industry, she pointed out that it could be particularly negative if the generic and authorised generic are sold at the same price. 

She believes if consumers are explained the difference between a generic and an authorised generic, they are more likely to choose the latter because it has the exact same substances as the original product.

“Other generic productions of the medicine will have the equivalent composition to the original brand but not the exact composition as generic brands will not have the original formula,” said Lutz.

Du Toit believes that pharmaceutical companies have valid cause to recover the tremendous costs associated with research and development, trials and testing.

“But they do engage in dubious practices to extend their exclusivity over a product, such as releasing different formats of a medication to extend the life of a patent,” she said.

“We always ask how this impacts the patient, and the greater good that could be achieved by a product – rather than focusing on the pure profitability of a product,” she concluded. 

Recent Articles

Featured How to be “future greedy” with passive income

Setting up numerous streams of income is a safe way to protect yourself from the loss of your main stream of income. Better yet, setting up passive streams of income will ensure you always have money coming in, without costing you additional working hours. So, what is “passive income”, and how can you earn this?

Can your debt be cancelled?

It sometimes happens that you struggle so much to pay your debt that you think of asking your creditor to write it off. But debt doesn’t just get written off. There are conditions that must be met and procedures that must be followed before the creditor cancels your debt.


Be financially prepared to lose your job – here’s how

During uncertain times, it’s natural to be concerned about the security of your job. Regardless of your performance at work, you may be out of work if your company is no longer profitable. But what would that mean for your personal finances, and how would you survive if you suddenly lost your income?

Should you save for a new car or finance it over time?

Buying a car is a long-term commitment. You either need to save up for it or pay it off over time, and the option you choose will depend on your personal circumstances and preferences. So, what should you consider when deciding which payment method to make use of?


FNB senior customers can earn up to 30% back in eBucks at Clicks

Price: Available on request
When: From 5 August 2020
Where: Nationwide

Bakwena Spa Women’s Day Special

Price: R549 per person
When: Until 31 August 2020
Where: Centurion, Hartbeespoort, Kuils River

Dis-Chem Pap Test Special

Price: R180
When: From 3 August to 11 September 2020
Where: Nationwide

Latest Guide

Guide to debt rehabilitation solutions